No Data
No Data
No Data
No Data
No Data
OncoSil Medical Raises AU$5.3 Million Under Entitlement Offer
OncoSil Medical (ASX:OSL) shareholders subscribed for a total of AU$5.3 million in the company's non-renounceable entitlement offer and shortfall offer, a Thursday filing with the Australian bourse re
MT NewswiresMay 2 09:42
OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial
OncoSil Medical (ASX:OSL) treated two more patients in the Netherlands using its implantable pancreatic cancer device, according to an April 17 filing with the Australian bourse. The treatment is part
MT NewswiresApr 18 06:52
OncoSil Medical Treats First Commercial Patient in Turkey With Implantable Pancreatic Cancer Device
OncoSil Medical (ASX:OSL) treated the first commercial patient in Turkey with its implantable OncoSil pancreatic cancer therapy device, according to a Tuesday filing with the Australian Securities Exc
MT NewswiresApr 16 08:53
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study
OncoSil Medical (ASX:OSL) on Friday announced the first patient treatment in the UK that utilized its pancreatic cancer device for its TRIPP-FXX clinical study. The study aims to assess the safety and
MT NewswiresApr 12 11:29
OncoSil Medical Obtains Device Reimbursement Approval in UK
OncoSil Medical (ASX:OSL) announced on Tuesday that its device can now be reimbursed at Imperial College Healthcare NHS Trust following an agreement with a large private insurance company in the UK, a
MT NewswiresApr 9 10:19
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device
OncoSil Medical (ASX:OSL) has penetrated another European market as two Austria-based patients received treatment using the OncoSil device for pancreatic cancer, according to a Friday filing with the
MT NewswiresApr 5 06:52
No Data
No Data